Results 41 to 50 of about 137,730 (260)
Applications and prospects of targeted therapy for neuroblastoma
World Journal of Pediatric Surgery, 2020 Background Neuroblastoma is an extremely malignant tumor in children. For advanced or recurrent cases, existing treatment modalities are limited and efficacy remains disappointing.
Jing Wang, Kai Li, Wei Yao
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan +3 more
wiley +1 more source
Frontiers in Molecular Neuroscience, 2019 Long non-coding RNAs (lncRNAs) have emerged as an important regulatory control in biological systems. Though the field of lncRNA has been progressing rapidly, a complete understanding of the role of lncRNAs in neuroblastoma pathogenesis is still lacking.
Bharat Prajapati +6 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background The Standards for Psychosocial Care for Children with Cancer and Their Families (“Standards”) are evidence‐based guidelines for psychosocial care in pediatric oncology. Care related to the three “Asking and Monitoring” Standards—Assessment of Psychosocial Needs, Assessment of Financial Needs, and Monitoring Neurocognitive Problems ...
Julia B. Tager +8 more
wiley +1 more source
Archives of Disease in Childhood - Fetal and Neonatal Edition, 1999 Over nine years, 33 children with neonatal neuroblastoma were registered with the UKCCSG (United Kingdom Children’s Cancer Study Group). Tumours of all stages were found, but stage 4S disease predominated. Five tumours were detected prenatally by ultrasonography. Treatment varied according to tumour stage. The overall survival of the group was 91%. Ten
J, Moppett, I, Haddadin, A B, Foot
openaire +2 more sources
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Scientific Reports, 2022 Neuroblastoma is a childhood tumour that is responsible for approximately 15% of all childhood cancer deaths. Neuroblastoma tumours with amplification of the oncogene MYCN are aggressive, however, another aggressive subgroup without MYCN amplification ...
Sanja Jurcevic +4 more
doaj +1 more source
Epigenetic reprogramming of lineage switching in cancer
FEBS Letters, EarlyView.Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Journal of Experimental & Clinical Cancer Research, 2021 Background High-risk neuroblastoma patients have a 5-year survival rate of less than 50%. It’s an urgent need to identify new therapeutic targets and the appropriate drugs.
Lijia Pan +5 more
doaj +1 more source